Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14
Listen now
Description
We’re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering. 💎 ABOUT THE SPEAKER I’ve “known” Bahija for over 10 years, after reading her profile in a student pharma magazine when I was studying bioengineering in France. At that time, she was head of MedImmune and SVP R&D at AstraZeneca. Now as the CEO of Immunocore, with their pioneering T cell receptor platform, she has helped to bring incredible treatments for cancer patients to market. 🔗 LINKS MENTIONED - Bahija on the Breakthrough Labs podcast - https://open.spotify.com/episode/2X4xedUdJid9GeioRSkCrP?si=39d8c7511aab443f - Immatics builds on its PRAME Success (and competes with Immunocore) - [OncologyPipeline.com](https://www.oncologypipeline.com/apexonco/immatics-builds-its-prame-success) 📜 TRANSCRIPT Read the full transcript here: 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:34] Welcome [00:01:46] Immunocore’s life-changing cancer drug [00:07:40] Commercializing Immunocore [00:13:46] Explaining the TCR technology [00:20:40] Targeting tumors with PRAME [00:23:26] Immunocore now and then [00:35:37] Why Bahija chose Immunocore [00:40:22] Top lessons from Bahija Jallal [00:45:48] How is risk appetite connected to innovation? [00:49:10] Diversity in biotech [01:00:59] Biological innovation [01:05:49] AI in protein engineering optimization [01:14:42] Thanks for listening
More Episodes
Published 03/26/24
We’re in Brussels with Edwin Moses, the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. We talk about how he feels 5 years after the exit from Ablynx and his lessons. We also talk about the parallels between industrial biotech, AI bio and cell...
Published 03/05/24
We’re in Copenhagen with Jens Nielsen, the CEO of BioInnovation Institute. We will talk about what works best to translate academic research in bio into innovation for humanity, especially how everything is connected. We also talk about how BII is solving some of the main challenges scientist...
Published 02/05/24